JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31

Benzinga Newsdesk www.benzinga.com Positive 85.0%

Neg 0% Neu 0% Pos 85%

JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $30 to $31.